Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a huma… Read more
Spyre Therapeutics Inc. (SYRE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.082x
Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has a cash flow conversion efficiency ratio of -0.082x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.12 Million) by net assets ($455.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Spyre Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Spyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Spyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spyre Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PROMOTORA OPER (AKY.SG)
STU:AKY
|
0.092x |
|
ALMONTY INDUSTRIES CDIS/1
F:ALI0
|
N/A |
|
FOSITEK CORP
TW:6805
|
-0.031x |
|
Geo-Jade Petroleum Corp
SHG:600759
|
-0.006x |
|
Synaptics Incorporated
NASDAQ:SYNA
|
0.022x |
|
Sealand Securities Co Ltd
SHE:000750
|
0.063x |
|
Corcept Therapeutics Incorporated
NASDAQ:CORT
|
0.059x |
|
Guaranty Trust Holding Co. PLC GDR
LSE:GTCO
|
0.232x |
Annual Cash Flow Conversion Efficiency for Spyre Therapeutics Inc. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Spyre Therapeutics Inc. from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $517.80 Million | $-157.41 Million | -0.304x | +44.01% |
| 2023-12-31 | $184.02 Million | $-99.91 Million | -0.543x | +65.92% |
| 2022-12-31 | $50.30 Million | $-80.14 Million | -1.593x | -148.96% |
| 2021-12-31 | $83.94 Million | $-53.72 Million | -0.640x | -18.09% |
| 2020-12-31 | $139.83 Million | $-75.78 Million | -0.542x | +50.44% |
| 2019-12-31 | $60.08 Million | $-65.69 Million | -1.093x | -129.01% |
| 2018-12-31 | $67.43 Million | $-32.19 Million | -0.477x | +2.36% |
| 2017-12-31 | $50.34 Million | $-24.61 Million | -0.489x | -63.43% |
| 2016-12-31 | $62.97 Million | $-18.84 Million | -0.299x | +1.63% |
| 2015-12-31 | $36.10 Million | $-10.98 Million | -0.304x | +92.24% |
| 2014-12-31 | $1.87 Million | $-7.33 Million | -3.918x | -- |